| symbol |
PTx |
|---|
| 会社名 | Pernix Therapeutics Holdings Inc. （パ―ニックス・セラピュ―ティクス・ホ―ルディングス） |
|---|
| 分野（sector） |
Health Care
ヘルスケア
|
|---|
| 産業（industry） |
Major Pharmaceuticals
|
|---|
| 業種 |
医薬品
医療関連（Health Care）
|
|---|
| 概要 |
事業概要 Pernix Therapeutics Holdings Inc. is a specialty pharmaceutical company. The Company focuses on identifying developing and commercializing differentiated products that address unmet medical needs. It focuses on underserved therapeutic areas such as central nervous system (CNS) including neurology and psychiatry as well as other specialty therapeutic areas. Its products include Treximet indicated for acute migraine; Zohydro ER with BeadTek an extended-release opioid agonist indicated for the management of pain severe; Silenor for the treatment of insomnia characterized by difficulty with sleep maintenance and Khedezla for major depressive disorder. It promotes selected non-core branded products such as its cough and cold products through co-promotion arrangements with third-party sales organizations and distributes its generic products through its subsidiaries Macoven Pharmaceuticals LLC (Macoven) and Cypress Pharmaceuticals Inc. パ―ニックス・セラピュ―ティクス・ホ―ルディングスは米国の医薬品製造持株会社。主に睡眠障害、細菌感染、咳や風邪などのブランド及びジェネリック医薬品を開発、製造。主な製品には、中耳感染症の抗生物質「CEDAX」、咳や風邪の治療薬「ZUTRIPRO」、「REZIRA」、「VITUZ」、不眠症治療薬「SILENOR(ドキセピン)」などがある。 Develops specialty pharmaceutical products
|
|---|
| 本社所在地 | 10 North Park Place Suite 201 Morristown NJ 07960 USA |
|---|
| 代表者氏名 | John A. Sedor ジョンA.セドール |
|---|
| 代表者役職名 | Chairman of the Board Chief Executive Officer 取締役会長兼最高経営責任者 |
|---|
| 電話番号 | +1 862-260-8457 |
|---|
| 設立年月日 | 35370 |
|---|
| 市場名 | NASDAQ National Market System |
|---|
| ipoyear | ―年 |
|---|
| 従業員数 | 274人 |
|---|
| url | www.pernixtx.com |
|---|
| nasdaq_url | https://www.nasdaq.com/symbol/ptx |
|---|
| adr_tso | ― |
|---|
| EBITDA | EBITDA（百万ドル） 19.85100 |
|---|
| 終値（lastsale） | 0.93 |
|---|
| 時価総額（marketcap） | 12945845.52 |
|---|
| 時価総額 | 時価総額（百万ドル） 9.88339 |
|---|
| 売上高 | 売上高（百万ドル） 131.23700 |
|---|
| 企業価値(EV) | 企業価値(EV)（百万ドル） 271.12339 |
|---|
| 当期純利益 | 当期純利益（百万ドル） -58.36000 |
|---|
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Pernix Therapeutics Holdings Inc revenues decreased 23% to $49.2M. Net loss decreased 37% to $32.1M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Lower net loss reflects Depreciation and amortization expense decrease of 69% to $11.3M (expense) Selling and Gen decrease of 10% to $35.5M (expense). |
|---|
PTX - パ―ニックス・セラピュ―ティクス・ホ―ルディングス （Pernix Therapeutics Holdings Inc.） パ―ニックス・セラピュ―ティクス・ホ―ルディングス